Literature DB >> 28052254

Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade.

Pornpimol Charoentong1, Francesca Finotello1, Mihaela Angelova1, Clemens Mayer1, Mirjana Efremova1, Dietmar Rieder1, Hubert Hackl1, Zlatko Trajanoski2.   

Abstract

The Cancer Genome Atlas revealed the genomic landscapes of human cancers. In parallel, immunotherapy is transforming the treatment of advanced cancers. Unfortunately, the majority of patients do not respond to immunotherapy, making the identification of predictive markers and the mechanisms of resistance an area of intense research. To increase our understanding of tumor-immune cell interactions, we characterized the intratumoral immune landscapes and the cancer antigenomes from 20 solid cancers and created The Cancer Immunome Atlas (https://tcia.at/). Cellular characterization of the immune infiltrates showed that tumor genotypes determine immunophenotypes and tumor escape mechanisms. Using machine learning, we identified determinants of tumor immunogenicity and developed a scoring scheme for the quantification termed immunophenoscore. The immunophenoscore was a superior predictor of response to anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) and anti-programmed cell death protein 1 (anti-PD-1) antibodies in two independent validation cohorts. Our findings and this resource may help inform cancer immunotherapy and facilitate the development of precision immuno-oncology.
Copyright © 2017 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cancer-germline antigens; neoantigens; predictive marker; tumor-infiltrating lymphocytes

Mesh:

Substances:

Year:  2017        PMID: 28052254     DOI: 10.1016/j.celrep.2016.12.019

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  1096 in total

1.  Tumor Heterogeneity Correlates with Less Immune Response and Worse Survival in Breast Cancer Patients.

Authors:  Kerry-Ann McDonald; Tsutomu Kawaguchi; Qianya Qi; Xuan Peng; Mariko Asaoka; Jessica Young; Mateusz Opyrchal; Li Yan; Santosh Patnaik; Eigo Otsuji; Kazuaki Takabe
Journal:  Ann Surg Oncol       Date:  2019-04-08       Impact factor: 5.344

2.  SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery.

Authors:  Siwen Hu-Lieskovan; Srabani Bhaumik; Kavita Dhodapkar; Jean-Charles J B Grivel; Sumati Gupta; Brent A Hanks; Sylvia Janetzki; Thomas O Kleen; Yoshinobu Koguchi; Amanda W Lund; Cristina Maccalli; Yolanda D Mahnke; Ruslan D Novosiadly; Senthamil R Selvan; Tasha Sims; Yingdong Zhao; Holden T Maecker
Journal:  J Immunother Cancer       Date:  2020-12       Impact factor: 13.751

Review 3.  B cells, plasma cells and antibody repertoires in the tumour microenvironment.

Authors:  George V Sharonov; Ekaterina O Serebrovskaya; Diana V Yuzhakova; Olga V Britanova; Dmitriy M Chudakov
Journal:  Nat Rev Immunol       Date:  2020-01-27       Impact factor: 53.106

4.  Potential effect of tumor-specific Treg-targeted antibodies in the treatment of human cancers: A bioinformatics analysis.

Authors:  Luigi Cari; Giuseppe Nocentini; Graziella Migliorati; Carlo Riccardi
Journal:  Oncoimmunology       Date:  2017-11-09       Impact factor: 8.110

5.  Cancer genomics: Keeping score with immunotherapy response.

Authors:  Dorothy Clyde
Journal:  Nat Rev Genet       Date:  2017-01-23       Impact factor: 53.242

6.  Germline Features Associated with Immune Infiltration in Solid Tumors.

Authors:  Sahar Shahamatdar; Meng Xiao He; Matthew A Reyna; Alexander Gusev; Saud H AlDubayan; Eliezer M Van Allen; Sohini Ramachandran
Journal:  Cell Rep       Date:  2020-03-03       Impact factor: 9.423

7.  Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma.

Authors:  Abhishek D Garg; Lien Vandenberk; Matthias Van Woensel; Jochen Belmans; Marco Schaaf; Louis Boon; Steven De Vleeschouwer; Patrizia Agostinis
Journal:  Oncoimmunology       Date:  2017-03-03       Impact factor: 8.110

Review 8.  Biomarker for personalized immunotherapy.

Authors:  Si-Yang Liu; Yi-Long Wu
Journal:  Transl Lung Cancer Res       Date:  2019-11

9.  Identification of an immune overdrive high-risk subpopulation with aberrant expression of FOXP3 and CTLA4 in colorectal cancer.

Authors:  Kaisa Cui; Surui Yao; Han Zhang; Mingyue Zhou; Bingxin Liu; Yulin Cao; Bojian Fei; Shenglin Huang; Zhaohui Huang
Journal:  Oncogene       Date:  2021-02-24       Impact factor: 9.867

Review 10.  Not all cancers are created equal: Tissue specificity in cancer genes and pathways.

Authors:  Joy J Bianchi; Xin Zhao; Joseph C Mays; Teresa Davoli
Journal:  Curr Opin Cell Biol       Date:  2020-02-21       Impact factor: 8.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.